Clinical Trial Detail

NCT ID NCT03234712
Title A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR) or Its Ligands
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors AbbVie
Indications

head and neck squamous cell carcinoma

lung squamous cell carcinoma

glioblastoma multiforme

colorectal cancer

Therapies

ABBV-321

Age Groups: senior adult

No variant requirements are available.